McKesson to Acquire Precision Medicine Group in $2.25 Billion Deal

BETHESDA, Md. (AP) — McKesson Corporation announced Monday that it will acquire privately held Precision Medicine Group in a transaction valued at approximately $2.25 billion, marking a significant expansion into the oncology and specialty care sectors. The agreement, finalized late Monday evening, positions the Irving, Texas-based healthcare services giant to accelerate growth in higher-margin therapeutic areas as it seeks to diversify beyond its traditional pharmaceutical distribution business.

The acquisition targets Precision Medicine Group's specialized capabilities in cancer treatment logistics and complex medication management. McKesson executives stated that the deal is designed to strengthen the company's portfolio within oncology, a segment experiencing robust demand driven by new drug approvals and shifting patient care models. By integrating Precision's infrastructure, McKesson aims to capture greater value in the specialty pharmacy market, where handling high-cost therapies requires distinct operational expertise.

Precision Medicine Group, based in Bethesda, Maryland, has built a reputation for managing intricate supply chains for oncology patients. The company's network includes specialized distribution centers and clinical support services tailored to the unique needs of cancer care. Under the terms of the agreement, Precision will operate as a standalone subsidiary within McKesson's Specialty Solutions division, allowing it to maintain its existing brand identity while leveraging McKesson's broader financial resources and technology platforms.

Industry analysts view the move as a strategic pivot for McKesson, which has faced pressure to demonstrate growth in areas beyond its core wholesale distribution operations. The healthcare sector has seen a surge in mergers and acquisitions as major players seek to consolidate supply chains and secure footholds in lucrative therapeutic categories. The $2.25 billion price tag reflects the premium placed on assets capable of navigating the complexities of modern cancer therapy delivery.

McKesson did not disclose specific financing details for the transaction, though the company indicated it would fund the acquisition through a combination of cash on hand and existing credit facilities. Regulatory approval is expected to be required before the deal can close, with no specific timeline provided for the completion of the merger. The announcement comes as federal regulators continue to scrutinize large-scale consolidations in the healthcare industry to ensure competitive markets are maintained.

While the acquisition represents a major step forward for McKesson's specialty care ambitions, questions remain regarding the integration timeline and potential workforce adjustments at Precision Medicine Group. Company spokespeople declined to comment on staffing plans or operational changes pending the finalization of regulatory reviews. The deal is expected to be completed within the next 12 months, subject to customary closing conditions.